{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019080","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.394636+00:00","generated_at":"2026-06-02T00:39:10.135217+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InspireMD Q1 revenue up 22% to $1.51M; net loss widens to $7.0M ($0.21/sh)","bullets":["Revenue $1.51M (+22% YoY); stent units sold 2,553 (+25.6% YoY).","Net loss $7.03M ($0.21/sh) vs $4.26M ($0.53/sh) in Q1 2023; operating expenses $7.71M (+62%).","Gross margin fell to 19.4% from 30.1% due to higher training costs.","Cash $34.0M; one-year C-GUARDIANS results to be presented at LINC 2024.","CE Mark recertified under MDR; Pete Ligotti appointed EVP/GM North America."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019080","json":"https://secwatch.observer/filing/0001493152-24-019080.json","markdown":"https://secwatch.observer/filing/0001493152-24-019080.md","text":"https://secwatch.observer/filing/0001493152-24-019080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224019080/0001493152-24-019080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224019080/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:39:10.135217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8d452837c0c40aa9edcd4365c7627a2ef93796e","claim":"InspireMD, Inc. reported first quarter ended March 31, 2024 results: revenue $1,511,000, net income $7,032,000, EPS $0.21 per basic and diluted share.","evidence_excerpt":"For the first quarter of 2024, total revenue increased 22.0%, to $1,511,000, from $1,239,000 during the first quarter of 2023. This increase was predominantly driven by growth in existing markets . Gross profit for the first quarter of 2024 decreased by $81,000, or 21.6%, to $292,000, compared to a gross profit of $373,000 for the first quarter of 2023. This decrease resulted primarily from higher training costs of new hires to build capacity for anticipated increased volume requirements . Gross margin (gross profit as a percentage of revenue) decreased to 19.4% during the three months ended March 31, 2024, from 30.1% during the three months ended March 31, 2023. Total operating expenses for the first quarter of 2024 were $7,706,000, an increase of $2,952,000, or 62.1% compared to $4,754,000 for the first quarter of 2023. This increase was primarily due to higher share-based compensation resulting from the recognition of grants made during the second quarter of 2023 and the first quart","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224019080/0001493152-24-019080-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$1,511,000"},{"label":"Net income","value":"$7,032,000"},{"label":"EPS","value":"$0.21 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}